SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Merck signs patent licensing agreement with Sun Pharma for Januvia: Report

29 Jun 2013 Evaluate

US drug firm Merck Sharp & Dhome and Indian drug-maker Sun Pharmaceuticals Industries, who have a co-marketing tie up for former’s diabetes drug Januvia, reportedly have now signed a patent licensing agreement. The move will further strengthen the patent infringement suit that the two companies have filed against Glenmark after the latter launched generic versions of Merck’s diabetes drugs Januvia & Janumet in India.

US drug firm Merck has now licensed its patents on Januvia to Sun Pharma in India, a mandatory procedural requirement, which was missing when Merck and Sun Pharma filed a patent infringement suit against Glenmark on April 1. The two companies have formalized the licensing agreement, signed on May 16 and registered in the Patent Office on May 21.

However, this patent case will not impact the existing marketing tie-up between the two companies. Back in 2011, Merck and Sun Pharma entered into a partnership for marketing blockbuster diabetes drug Sitagliptin and one of its combinations in the country. Under the India-specific agreement, Sun Pharma will market the anti-diabetes drugs under different brand names, while Merck, which holds the patent, will continue to market Sitagliptin as Januvia.

Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×